#genetic disorders

NORD Applauds FDA Initiative to Develop New Regulatory Framework for Rare Disease Drug Development

NORD Applauds FDA Initiative to Develop New Regulatory Framework for Rare Disease Drug Development

NORWELL, Mass. — The National Organization for Rare Disorders (NORD®) has issued a strong statement of support for...

NORD Announces Request for Applications to Implement Two New Patient Registries on the IAMRARE Platform with Support from Critical Path Institute

NORD Announces Request for Applications to Implement Two New Patient Registries on the IAMRARE Platform with Support from Critical Path Institute

NORWELL, Mass. — The National Organization for Rare Disorders (NORD®) has officially announced a new request for applications...

NORD Announces Request for Applications to Implement Two New Patient Registries on IAMRARE® Platform

NORD Announces Request for Applications to Implement Two New Patient Registries on IAMRARE® Platform

NORWELL, Mass. — The National Organization for Rare Disorders (NORD®) has officially announced a new request for applications...

NORD Announces Request for Applications to Implement Two New Patient Registries on IAMRARE® Platform with Support from Critical Path Institute

NORWELL, Mass. — The National Organization for Rare Disorders (NORD®) has officially announced a new request for applications aimed at...

NORD and Critical Path Institute Announce Funding Opportunity to Launch Two New Patient Registries on the IAMRARE Platform

NORWELL, Mass. — The National Organization for Rare Disorders (NORD®) has officially announced a new request for applications aimed at...

NORD Announces Funding Opportunity to Launch Two New Rare Disease Patient Registries on the IAMRARE Platform

NORWELL, Mass., Oct. 21, 2026 — The National Organization for Rare Disorders (NORD®) has officially announced a new request for...

NORD and Critical Path Institute Announce Funding Opportunity to Launch Two New Rare Disease Patient Registries on the IAMRARE Platform

NORWELL, Mass., Oct. 21, 2026 — The National Organization for Rare Disorders (NORD®) has officially announced a new request for...

BioMarin, Jazz Pharmaceuticals, and Otsuka CEOs Join NORD Leadership for High-Level Dialogue on Turning Scientific Breakthroughs into Patient Progress

WASHINGTON, D.C. and NORWELL, Mass. — As the landscape of medical science continues to evolve at a breathtaking pace, the...

NORD Applauds FDA Initiative to Establish New Regulatory Framework for Rare Disease Drug Development

NORWELL, Mass. — In what patient advocates are hailing as a monumental step forward for millions of families, the National...

NORD Applauds FDA’s Landmark Initiative to Establish Tailored Regulatory Framework for Rare Disease Drug Development

NORWELL, Mass. — The National Organization for Rare Disorders (NORD®) has issued a resounding endorsement of the U.S. Food and...

Muat Lebih Banyak